FOLH1
ENSG00000086205
Target class
Enzyme
Chromosome
11
Approved drugs
1
Clinical candidates (approved and in development)
8
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- No
- Target name
- FOLH1
- Gene name
- Folate hydrolase 1
- Gene symbol
- FOLH1
- Previous gene symbols
- FOLH
- Protein name
- Glutamate carboxypeptidase 2 (EC 3.4.17.21) (Cell growth-inhibiting gene 27 protein) (Folate hydrolase 1) (Folylpoly-gamma-glutamate carboxypeptidase) (FGCP) (Glutamate carboxypeptidase II) (GCPII) (Membrane glutamate carboxypeptidase) (mGCP) (N-acetylated-alpha-linked acidic dipeptidase I) (NAALADase I) (Prostate-specific membrane antigen) (PSM) (PSMA) (Pteroylpoly-gamma-glutamate carboxypeptidase)
- PSM
- PSMA
- NAALAD1
- NAALAdase
- GCP2
- GCPII
- Gene biotype
- Protein coding
- Gene family
- M28 metallopeptidases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 27
- Highest tissue expression
- 60.73
- Tissue specificity (Gini)
- 0.751
- Tissue specificity (tau)
- 0.934
- KEGG gene identifiers
- hsa:2346
- Reactome pathways
- R-HSA-8963693
- Protein interaction confidence
- 0.823333
- Protein interaction partners
- 21
- End position
- 49208640
- Start position
- 49145092
- Chromosome
- 11
- Strand
- Reverse
- Cell membrane
- Single-pass type II membrane protein .
- SUBCELLULAR LOCATION: [Isoform PSMA']: Cytoplasm .
Publication evidence
- PubMed 9809977
- Tissue specificity (tau)
- 0.933712
- Expression inequality (Gini)
- 0.751272
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)
- 60.73
- Prostate
- 50.96
- Brain - Substantia nigra
- 21.56
- Brain - Hippocampus
- 17.18
- Minor Salivary Gland
- 13.9
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)60.73
- Prostate50.96
- Brain - Substantia nigra21.56
- Brain - Hippocampus17.18
- Minor Salivary Gland13.9
- Brain - Putamen (basal ganglia)13.21
- Brain - Amygdala10.94
- Brain - Caudate (basal ganglia)9.82
- Nerve - Tibial9.48
- Brain - Hypothalamus8.67
- Brain - Nucleus accumbens (basal ganglia)5.17
- Liver4.93
- Brain - Frontal Cortex (BA9)4.67
- Brain - Cortex4.67
- Spleen2.68
- Brain - Anterior cingulate cortex (BA24)2.68
- Fallopian Tube2.59
- Brain - Cerebellum2.36
- Kidney - Cortex2.32
- Brain - Cerebellar Hemisphere2.2
- Lung1.9
- Kidney - Medulla1.73
- Breast - Mammary Tissue1.67
- Cervix - Endocervix1.57
- Skin - Sun Exposed (Lower leg)1.34
And 29 more, listed on the interactive page.
- GO:0006508
- GO:0097054
- GO:0098829
- GO:1900451
- GO:0005737
- GO:0005886
- GO:0009986
- GO:0016020
- GO:0070062
- GO:0004181
- GO:1904492
- GO:1904493
Related records
Trials (54)
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
- 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
- 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
- 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
- 177Lu-PSMA-617 Managed Access Program for mCRPC Patients
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
- 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
- 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
- 177LuPSMA in Renal Cell Carcinoma
- A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
- A Study of 177Lu-PSMA-617 in People With Gliomas
- A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
- A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
- Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
Drugs (9)
- CYT-500 177LU Glutamate carboxypeptidase II binding agent
- HUJ591 111IN Glutamate carboxypeptidase II binding agent
- HUJ591 177LU Glutamate carboxypeptidase II binding agent
- J591 177LU Glutamate carboxypeptidase II binding agent
- Lutetium LU-177 vipivotide tetraxetan Glutamate carboxypeptidase II binding agent
- MDX-070 Glutamate carboxypeptidase II other
- MLN-2704 Glutamate carboxypeptidase II binding agent
- Vipivotide tetraxetan lutetium Glutamate carboxypeptidase II binding agent
- Yttrium Y 90 capromab pendetide Glutamate carboxypeptidase II binding agent